Riluzol as treatment of the amyotrophic lateral sclerosis;Riluzol como tratamiento de la esclerosis lateral amiotrofica

Revista de Neurologia

Volumn 27, Issue 160, 1998, Pages 1021-1027

  Borras Blasco J ^a   Plaza Macias I ^a   Navarro Ruiz, A ^a   Peris Marti J ^a   Anton Cano A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Amyotrophic lateral sclerosis; Riluzol

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; GLUTAMIC ACID; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; MULTICENTER STUDY; NERVE CELL DEGENERATION; NEUROTRANSMISSION; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032419880     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.27160.98127     Document Type: Article

References (47)

1. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991; 66: 54-82.
2. Appel S, Smith RG. Can neurotrophic factors prevent or reverse motor-neuron injury in amyotrophic lateral sclerosis? Exp Neurol 1993; 124: 100-2.
3. Kaplan L, Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994; 15: 675-8.
4. Mackay R. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963; 8: 117-27.
5. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-8.
6. Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993; 341: 265-8.
7. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familiar amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
8. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-5.
9. Sanders KA, Rowland LP, Murphy PL, Younger DS, Latov N, Sherman WH, et al. Motor neuron diseases and ALS: GM1 antibodies and paraproteinemia. Neurology 1993; 43: 418-20.
10. Rowland LP, Sherman WH, Latov N, Lange DJ, McDonald TD, Younger DS, et al. Amyotrophic lateral sclerosis and lymphoma: bone marrow examination and other diagnostic tests. Neurology 1992; 42: 1101-2.
11. Kornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, et al. The clinical correlates of high titer IgG anti GM1 antibodies. Ann Neurol 1994; 35: 234-7.
12. Bensimon G, Lacomblez L, Meininger V. The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 30: 585-91.
13. Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1993; 118: 169-74.
14. Appel SH. A unifying hypothesis for the course of amyotrophic lateral sclerosis, parkinsonism and Alzheimer disease. Ann Neurol 1981; 10: 499-505.
15. Couratier Ph, Sindou Ph, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in AlS CSF toxicity. Neuroreport 1994; 5: 1012-4.
16. Lipton S, Rosenberg P. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-20.
17. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflügers Arch 1991; 419: 603-9.
18. Hubert JP, Doble A. Ibotenic acid stimulated D-[3Hl-aspartate] release from cultured cerebellar granule cells. Neurosci Lett 1989; 96: 345-50.
19. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CAl. Eur J Pharmacol 1993; 250: 473-6.
20. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992; 147: 209-12.
21. Benavides J, Camelin JC, Mitran N, Flamand F, Uzan A, Legrand JJ, et al. 2-amino-6-trifluorpmethoxybenzothiazole, a possible antagonist of excitatory amino acid neurotransmission-II: biochemical properties. Neuropharmacology 1985; 24: 1085-92.
22. Hubert JP, Delumeau JC, Glowinski J, Premont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994; 113: 261-7.
23. 3H-GABA from cultured mouse cerebral cortex interneurons. J Neurosci 1987; 7: 2910-9.
24. Girdlestone D, Dupuy A, Cosion A. Riluzole antagonizes excitatory amino acid-evoked firing in rat facial motoneurons in-vivo. Br J Pharmacol 1989; 97 (Suppl): 583P.
25. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196-203.
26. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol 1995; 280: 47-53.
27. Gurney ME, Cutting FR, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-57.
28. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM, el al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992; 140: 225-30.
29. Wathl F, Allix M, Plotkine M, Boulu RG. Effect of riluzole on focal cerebral ischaemia in rats. Eur J Pharmacol 1993; 230: 209-14.
30. Stutzmann JM, Pratt J, Boraud T, Gross C. The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 1996; 7: 387-92.
31. Benazzouz A, Boraud T, Dubédat P, Boireau A, Stutzmann JM, Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995; 294: 299-307.
32. Boireau A, Dubédat P, Bordier F, Meunier M, Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994; 5: 2657-60.
33. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutaminergic neurotransmission. Neurosci Lett 1995; 201: 92-6.
34. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, et al. 2-amino-6-trifiuoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission-I: anticonvulsant properties. Neuropharmacology 1985; 24: 767-73.
35. Stutzmann J-M, Bohme GA, Gandolio G, Gottesmann C, Lafforgue J, Blanchard JC, et al. Riluzole prevents hyperexcitability produced by the mast cell degranulation peptide and dendrotoxin I in the rat. Eur J Pharmacol 1991; 193: 223-9.
36. Romettino S, Lazdunski M, Gottesmann C. Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur J Pharmacol 1991; 199: 371-3.
37. Saletu B, Grünberger J, Anderer P, Linzmayer L. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Methods Find Exp Clin Pharmacol 1996; 18: 55-66.
38. Riluzole prescribing information. Collegeville, PA: Rhône-Poulenc Rorer; 1996.
39. Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997; 282: 1465-72.
40. Bruno R, Vivier N, Montay G, Le Liboux A, Powe LK, Delumeau JC, Rhodes GR. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther 1997; 62: 518-26.
41. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31.
42. Package insert. Rilutek (riluzole). Collegeville, PA: Rhône-Poulenc Rorer, Revised December 1995.
43. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Phamacokinet 1995; 28: 449-57.
44. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82.
45. McKee P, Fuller G, Stevens D. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994; 331: 272.
46. Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1997; 49: 657-9.
47. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escortai 'Clinical Limits of Amyotrophic Lateral Sclerosis' Workshop Contributors. El Escorial World Federation of Neurology criteria for diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 (Suppl): 96-107.